@article{article, title  = {{3069MO Health-related quality of life (HRQoL) outcomes from the NIAGARA trial of perioperative durvalumab (D) plus neoadjuvant chemotherapy (NAC) in muscle-invasive bladder cancer (MIBC)}},

 publisher = {{Elsevier BV}},

 url = {{https://doi.org/10.1016/j.annonc.2025.08.3683 }},

 year = {{2025}},

 month = {{9}},

 author = {{van der Heijden MS and Powles TB and Galsky MD and Catto JWF and Meeks J and Zukov R and Izumi K and Huang KH and Hacioglu MB and Hussain SA and Necchi A et al}},

 doi = {{10.1016/j.annonc.2025.08.3683}},

 volume = {{36}},

 journal = {{Annals of Oncology}},

 pages = {{S1588-S1588}},

 note = {{Accessed on 2025/12/12}}}